Analysed BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
29-06-2026
yahoo.com
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
30-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
30-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading
01-07-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
02-07-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
20-07-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
22-07-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
24-07-2026
yahoo.com
What is the current price of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The current price of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is $1.48.
BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) since the previous trading day is $-0.09.
BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) since the previous trading day is -5.7325%.
What is the most recent average sentiment score for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The most recent average sentiment score for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is 38 out of 100.
What is the most recent average sentiment for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The most recent sentiment for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is .
SEC-8K** Filing Available For BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.